<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357666</url>
  </required_header>
  <id_info>
    <org_study_id>HUDC-VT-201</org_study_id>
    <nct_id>NCT03357666</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy of HUDC_VT in Patients With Bacterial Vaginosis</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Parallel Design, Multicenter Phase II Trial to Evaluate the Efficacy and Safety of HUDC_VT in Patients With Bacterial Vaginosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haudongchun Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haudongchun Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The objective of the study is to confirm the pharmacological mechanism and evaluate the
      efficacy and safety after HUDC-VT administration compared to placebo in patients with
      bacterial vaginosis.

      Vaginitis in adult women is extremely common and it often results in marked suffering.
      Epidemiologic studies indicate the high prevalence of vaginitis and the large number of
      causes in US.

      The broad-spectrum antibiotics such as metronidazole have been used as a treatment of
      vaginitis.However, it is not desirable using of these antibiotics caused appearance of
      resistant bacterium and killing normal bacterium including lactobacillus.

      In addition, it has been reported that long term treatment of antibiotics can be caused body
      toxicity through absolution by vagina.

      The product, HUDC_VT, is a effective and safe vaginal tablet composed glucose and sodium
      chloride for treatment of vaginitis by preserving healthy condition in vagina.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2016</start_date>
  <completion_date type="Anticipated">March 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic cure rate of bacterial vaginosis at 2 weeks after last treatment</measure>
    <time_frame>at 2 weeks after last treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Therapeutic cure rate of bacterial vaginosis at last treatment</measure>
    <time_frame>at 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with Normal Nugent score</measure>
    <time_frame>at 2 weeks after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with Normal Hay/Ison grade</measure>
    <time_frame>at 2 weeks after last treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with Normal Vaginal Fluid pH</measure>
    <time_frame>at 2 weeks after last treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <condition>HUDC_VT</condition>
  <condition>Haudongchun</condition>
  <arm_group>
    <arm_group_label>HUDC_VT(Glucose 200mg/Sodium chloride 200mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucose 200mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HUDC_VT(Glucose 400mg/Sodium chloride 200mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucose 400mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HUDC_VT(Glucose 400mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glucose 400mg, once a day, two tablets at a time for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HUDC_VT(Sodium chloride 200mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium chloride 200mg, once a day, two tablets at a time for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, once a day, two tablets at a time for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HUDC_VT(Glucose 200mg/Sodium chloride 200mg)</intervention_name>
    <description>Vaginal administration, two tablets once a day for 7 days</description>
    <arm_group_label>HUDC_VT(Glucose 200mg/Sodium chloride 200mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HUDC_VT (Glucose 400mg/Sodium chloride 200mg)</intervention_name>
    <description>Vaginal administration, two tablets once a day for 7 days</description>
    <arm_group_label>HUDC_VT(Glucose 400mg/Sodium chloride 200mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HUDC_VT (Glucose 400mg)</intervention_name>
    <description>Vaginal administration, two tablets once a day for 7 days</description>
    <arm_group_label>HUDC_VT(Glucose 400mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HUDC_VT (Sodium chloride 200mg)</intervention_name>
    <description>Vaginal administration, two tablets once a day for 7 days</description>
    <arm_group_label>HUDC_VT(Sodium chloride 200mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vaginal administration, two tablets once a day for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Fertile women

          2. Clinical diagnosis of bacterial vaginosis with criteria on below (3 out of 4 fulfilled
             criteria)

               -  light gray adherent vaginal discharge

               -  pH &gt;4.5

               -  Presence of clue cells ≥20%

               -  Positive &quot;10% KOH whiff test&quot;

          3. Nugent Score ≥ 4

        Exclusion Criteria:

          1. Pregnant or breast-feeding patient or planning pregnancy

          2. Patient with candidiasis, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria
             gonorrhoeae or Herpes simplex virus infection

          3. Patient who received antifungal or antimicrobial therapy (systemic or intravaginal)
             within 30 days of randomization

          4. Any condition or circumstance that would interfere with analysis of study results

          5. Patient who have a plan to treat other disease (e.g cervical carcinoma) during
             clinical study period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WonSeog Choi</last_name>
    <role>Study Chair</role>
    <affiliation>Haudongchun Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MiYeon Choi</last_name>
    <phone>+82 70-7729-5704</phone>
    <email>cbg@hudc.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Guro-gu</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JaeKwan Lee</last_name>
      <phone>+82 2-2626-1200</phone>
      <email>jklee38@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>JaeKwan Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2017</study_first_submitted>
  <study_first_submitted_qc>November 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

